

# Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma

|  |   |  |
|--|---|--|
| <b>Submission date</b><br>27/11/2020   | <b>Recruitment status</b><br>No longer recruiting | <input type="checkbox"/> Prospectively registered<br><input checked="" type="checkbox"/> Protocol            |
| <b>Registration date</b><br>18/01/2021 | <b>Overall study status</b><br>Ongoing            | <input type="checkbox"/> Statistical analysis plan<br><input type="checkbox"/> Results                       |
| <b>Last Edited</b><br>04/03/2024       | <b>Condition category</b><br>Cancer               | <input type="checkbox"/> Individual participant data<br><input type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-ixazomib-lenalidomide-and-dexamethasone-for-people-with-myeloma-fitness>

### Background and study aims

Myeloma is a type of bone marrow cancer diagnosed in around 5500 patients in the UK each year. The development of treatments has increased life expectancy in all patients, but these have been less effective in older and frailer patients. There is no evidence to suggest their myeloma is more aggressive, so it needs to be asked why this is the case. Research is beginning to look at older myeloma patients who are ineligible for transplants. Myeloma XI, a previous trial where 1840 of these patients were recruited, has shown that treatment outcomes were not necessarily associated with different combinations of treatment. The aim of this study is to compare standard and frailty-adjusted induction treatment with ixazomib, lenalidomide and dexamethasone and maintenance lenalidomide to lenalidomide plus ixazomib.

### Who can participate?

Newly diagnosed myeloma patients, above the age of 18, who are not eligible for a stem cell transplant

### What does the study involve?

All participants receive induction treatment with ixazomib, lenalidomide and dexamethasone and are randomly allocated to either frailty score-adjusted treatment or standard upfront treatment followed by toxicity-dependent dose modifications during treatment. Following 12 cycles of induction treatment participants alive and progression-free undergo a second randomisation. In the second phase of the trial, patients will be tested to assess whether lenalidomide and ixazomib are effective as a maintenance treatment. Patients will either receive lenalidomide and ixazomib, or lenalidomide and placebo (something that has a similar taste and appearance to ixazomib but has no effect on the person) to test this.

### What are the possible benefits and risks of participating?

Evidence from previous trials has shown that patients who are older and living with other health

issues do not stay on standard treatment for as long as younger, fitter patients. This study will explore whether tailoring the medication will increase the durability of treatment in older patients to ensure a longer benefit and therefore reduce the risk of having to stop treatment early due to side effects. Participants will be helping to answer important questions and it is hoped that this will improve treatment now and for future patients.

At the moment, neither the IRD induction treatment nor maintenance therapy with either lenalidomide alone or in combination with ixazomib is available on the NHS for the treatment of newly diagnosed myeloma, and so this study gives access to these treatments. Previous studies have shown that maintenance therapy with lenalidomide can increase the length of disease remission. The goal of this study is to gain a greater understanding of the various treatment options available for myeloma patients, how they compare to each other and how they are best delivered to patients. This may or may not be a better approach to treating myeloma compared to what doctors do currently.

There are potential risks associated with the study as well as potential side effects from the trial treatments and drugs. A small number of patients may develop additional types of cancer, and it is possible that this risk may be increased with lenalidomide treatment. Some medications, and complementary health supplements such as St John's Wort, should not be used during this study as they may interact with the study medications.

Patients who take part in this study are potentially at risk of becoming sterile or infertile. This is also the case with other chemotherapy treatments participants would likely receive if they were not on the study. If appropriate, counselling and a referral for fertility assessment and preservation will be available. Some patients with myeloma find that they can continue to work during treatment.

Where is the study run from?  
University of Leeds (UK)

When is the study starting and how long is it expected to run for?  
August 2017 to August 2027

Who is funding the study?  
The study is largely funded by Cancer Research UK. Some of the costs of the drugs being used in the study, as well as some additional funding for the running of the study, is being provided by the companies who make two of the drugs being investigated, Takeda (ixazomib) and Celgene (lenalidomide).

Who is the main contact?  
Rowena Henderson  
ctr\_u\_myelomaxiv@leeds.ac.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Ms Rowena Henderson

**Contact details**  
Leeds Institute of Clinical Trials Research  
Clinical Trials Research Unit

University of Leeds  
Leeds  
United Kingdom  
LS2 9JT  
+44 (0)113 343 1159  
ctru\_myelomaxiv@leeds.ac.uk

### **Type(s)**

Public

### **Contact name**

Ms Sharon Gillson

### **Contact details**

Leeds Institute of Clinical Trials Research  
Clinical Trials Research Unit  
University of Leeds  
Leeds  
United Kingdom  
LS2 9JT  
+44 (0)113 34 39368  
ctru\_myelomaxiv@leeds.ac.uk

## **Additional identifiers**

### **EudraCT/CTIS number**

2018-003590-10

### **IRAS number**

234453

### **ClinicalTrials.gov number**

NCT03720041

### **Secondary identifying numbers**

Version 2.0, 10th October 2019, IRAS 234453

## **Study information**

### **Scientific Title**

A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (IR)

### **Acronym**

FiTNEss (UK-MRA Myeloma XIV)

### **Study objectives**

At R1:

That there is a difference in the proportion of patients, categorised as “unfit” or “frail” at trial

entry, requiring early cessation of treatment (within 60 days of randomisation) between standard up-front (reactive) or frailty score-adjusted (adaptive) dose modifications, with superiority of the frailty score-adjusted (adaptive) dose modifications anticipated. The null hypothesis is that there is no difference.

At R2:

That there is a difference in progression-free survival between lenalidomide + placebo (R) and lenalidomide + ixazomib (R + I) maintenance therapy with superiority of R + I maintenance therapy anticipated. The null hypothesis is that there is no difference.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 11/09/2019, North East – Tyne & Wear South Research Ethics Committee (NHSBT Newcastle Blood & Transplant Centre Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44(0) 207 1048084; nrescommittee.northeast-tyneandwearsouth@nhs.net), REC ref: 19/NE/0215

### **Study design**

Multicenter interventional placebo-controlled double-blind randomized controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details to request a patient information sheet.

### **Health condition(s) or problem(s) studied**

Multiple myeloma

### **Interventions**

All participants receive 12 cycles of induction treatment with ixazomib, lenalidomide and dexamethasone and are randomised on a 1:1 basis at trial entry to the use of frailty score-adjusted up-front dose reductions vs. standard up-front dosing followed by toxicity dependent reactive dose modifications during therapy.

Randomisation 1 will be completed using a computer generated minimisation algorithm that incorporates a random element to ensure that all arms are well balanced for specific participant characteristics, details of which will be required at randomisation.

Participants randomised to the frailty adjusted arm will undergo assessment for frailty according to the IMWG Frailty Index be categorised as fit, unfit or frail.

Following 12 cycles of induction treatment participants alive and progression-free undergo a second randomisation on a 1:1 basis to maintenance treatment with lenalidomide plus placebo versus lenalidomide plus ixazomib. Participants and their treating physicians will be blinded to maintenance allocation.

Randomisation 2 will be completed using a computer generated minimisation algorithm that incorporates a random element to ensure that all arms are well balanced for specific participant characteristics, details of which will be required at randomisation.

Ixazomib is an oral hard gelatin capsule that is taken orally.

Lenalidomide is a hard capsule that is taken orally.

Dexamethasone is a hard capsule that is taken orally.

The placebo is an oral hard gelatin capsule that is taken orally.

All participants will receive 12 cycles of induction treatment, each treatment cycle is 28 days in length.

Participants who are randomised to the standard up-front dosing followed by toxicity dependent dose-modifications (reactive) arm will receive:

4 mg of ixazomib on days 1, 8 and 15

25 mg of lenalidomide on days 1-21

40 mg of dexamethasone in participants  $\leq 75$  years or 20 mg dexamethasone in participants  $> 75$  years on days 1, 8, 15, 22

Participants randomised to the frailty score-adjusted dosing arm (adaptive) and are categorised as FIT will receive:

4 mg of ixazomib on days 1, 8 and 15

25 mg of lenalidomide on days 1-21

40 mg of dexamethasone on days 1, 8, 15, 22

Participants randomised to the frailty score-adjusted dosing arm (adaptive) and are categorised as UNFIT will receive:

4 mg of ixazomib on days 1, 8 and 15

15 mg of lenalidomide on days 1-21

20 mg of dexamethasone on days 1, 8, 15, 22

Participants randomised to the frailty score-adjusted dosing arm (adaptive) and are categorised as FRAIL will receive:

4 mg of ixazomib on days 1, 8 and 15

10 mg of lenalidomide on days 1-21

10 mg of dexamethasone on days 1, 8, 15, 22

Participants who progress to maintenance and are randomised to receive lenalidomide and placebo will receive:

10 mg of lenalidomide on days 1-21

4 mg of placebo on days 1, 8, 15

Participants who progress to maintenance and are randomised to receive lenalidomide and placebo will receive:

10 mg of lenalidomide on days 1-21  
4 mg of ixazomib on days 1, 8, 15

The duration of trial treatment for individual participants will vary, as treatment will continue until disease progression or intolerable toxicity. On average, it is expected that a participant will receive trial treatment for an average of 37 months: they will receive 12 cycles of IRD induction, followed by a median of 25 cycles of maintenance. All cycles last for 28 days.

## **Intervention Type**

Drug

## **Phase**

Phase III

## **Drug/device/biological/vaccine name(s)**

Ixazomib, lenalidomide, dexamethasone

## **Primary outcome measure**

Randomisation 1 (R1): Early treatment cessation (yes or no). Participants will be defined to have ceased treatment early if they die, progress, or are withdrawn from treatment (by a treating clinician) or withdraw consent for trial treatment, within 60 days of R1.

Randomisation 2 (R2): Progression-free survival (PFS-R2): time of first documented evidence of disease progression or death from any cause. Individuals who are lost to follow-up or progression-free at the time of analysis will be censored at their last known date to be alive and progression-free

## **Secondary outcome measures**

Measured using eCRFs and patient records unless otherwise indicated:

1. Progression-free survival (PFS-R1): the time from R1 to the time of first documented evidence of disease progression or death from any cause. Disease progression is defined according to the IMWG Uniform Response Criteria for Multiple Myeloma
2. Time to progression: the time from randomisation to the date of first documented evidence of disease progression
3. Time to Progression-free survival two (PFS2): time from randomisation to the time of the second documented disease progression or death from any cause
4. Overall survival (OS): the time from randomisation to the time of death from any cause
5. Survival after progression: time from the date of first documented evidence of disease progression to the date of death from any cause
6. Death within 12 months of R1 (yes or no)
7. Overall response rate (ORR): whether a participant had sCR, CR, VGPR, PR, MR, SD or PD at the end of induction according to the IMWG Uniform Response Criteria for Multiple Myeloma
8. Attainment of  $\geq$ VGPR (yes or no)
9. Attainment of Minimal Residual Disease (MRD) negativity (yes or no, according to the IMWG MRD criteria)
10. Duration of response (DoR): time from the first observation of response  $\geq$  PR, following R1, to the time of first documented evidence of disease progression or death confirmed related to progression
11. Time to improved response: time from the date of R2 to the date the response category is first improved based on the Modified International Uniform Response Criteria for Multiple Myeloma

12. Time to next treatment: time from R1 to the start date of the next line of treatment (i.e. treatment following documented evidence of progressive disease) or death from any cause
13. Treatment compliance and total amount of therapy delivered:
- 13.1. Did the participant receive 12 cycles of induction treatment (yes or no)
- 13.2. Number of induction and maintenance cycles which the participant received. This may be extended to consider the percentage of protocol dose delivered. For each treatment (ixazomib, lenalidomide, dexamethasone) this will be defined as the total dose received in a cycle compared to the total dose the participant should have received in the cycle without modifications, averaged across all cycles of treatment
14. Toxicity and safety reported based on the adverse events, as graded by CTCAE V5 and determined by routine clinical assessments at each centre. The number of SAEs will be reported according to MedDRA System Organ Class. All second primary malignancies will be reported based on information collected on the CRF
15. Quality of Life (QoL) using the patient-reported outcome measures; EORTC-QLQ-C30, EORTC-QLQ-MY20 and EQ-5D (3 Level) at R1, after cycles 2,6 and 12 during induction treatment. They are also collected after cycles 6 and 12 during maintenance treatment
16. Cost-effectiveness: cost per incremental QALY below £20,000 and/or a positive incremental net monetary benefit. For R1, the cost-effectiveness of standard dose IRD vs frailty adjusted dose IRD will be analysed. For R2, the cost-effectiveness of maintenance therapy using R vs R+I will be analysed

Added 07/07/2022:

17. Event-free survival (EFS) is measured from randomisation to the first instance of one of the following events; death, progression, discontinuation of the randomised treatment, a grade 4 haematological toxicity or a non-haematological toxicity  $\geq$  grade 3

### **Overall study start date**

15/08/2017

### **Completion date**

31/08/2027

## **Eligibility**

### **Key inclusion criteria**

Inclusion criteria for Randomisation 1 (R1):

1. Newly diagnosed as having MM according to the updated IMWG diagnostic criteria 2014 requiring treatment
2. Not eligible for stem cell transplant
3. Aged at least 18 years
4. Meet all of the following blood criteria within 14 days before R1:
  - 4.1. Haematological:
    - 4.1.1. Absolute neutrophil count (ANC)  $\geq 1 \times 10^9/\text{l}$ . Unless the participant has a known /suspected diagnosis of familial or racial neutropenia in which case an ANC  $\geq 0.75 \times 10^9/\text{l}$  is allowed. The use of growth factor support is permitted
    - 4.1.2. Platelet count  $\geq 50 \times 10^9/\text{l}$ , or, in the case of heavy bone marrow infiltration ( $\geq 50\%$ ) which in the opinion of the investigator is the cause of the thrombocytopenia and provided appropriate supportive measures and patient monitoring are in place, platelet count  $\geq 30 \times 10^9/\text{l}$  is permitted. Please note: Platelet transfusions are not allowed  $\leq 3$  days prior to randomisation in order to meet these values
    - 4.1.3. Haemoglobin  $\geq 80 \text{ g/l}$ . The use of red blood cell transfusions is permitted

#### 4.2. Biochemical:

4.2.1. Total bilirubin  $\leq 3 \times$  upper limit of normal (ULN)

4.2.2. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)  $\leq 3 \times$  ULN

5. Meet the pregnancy prevention requirements

6. Able to provide written informed consent

#### Inclusion criteria for Randomisation 2 (R2):

1. Randomised into the FiTNEss (Myeloma XIV) trial and received induction chemotherapy with ixazomib and lenalidomide continued for 12 cycles

2. Achieved at least MR at the end of IRD induction according to the IMWG Uniform Response Criteria for Multiple Myeloma, with no evidence of progression prior to R2

3. Meet all of the following blood criteria within 14 days before R2:

##### 3.1. Haematological:

3.1.1. Absolute neutrophil count (ANC)  $\geq 1 \times 10^9/\text{l}$ . Unless the participant has a known /suspected diagnosis of familial or racial neutropenia in which case an ANC  $\geq 0.75 \times 10^9/\text{l}$  is allowed. The use of growth factor support is permitted

3.1.2. Platelet count  $\geq 50 \times 10^9/\text{l}$ . Please note: Platelet transfusions are not allowed  $\leq 3$  days prior to randomisation in order to meet these values

3.1.3. Haemoglobin  $\geq 80 \text{ g/l}$ . The use of red blood cell transfusions is permitted

##### 3.2. Biochemical:

3.2.1. Total bilirubin  $\leq 3 \times$  upper limit of normal (ULN)

3.2.2. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)  $\leq 3 \times$  ULN

#### Participant type(s)

Patient

#### Age group

Adult

#### Lower age limit

18 Years

#### Sex

Both

#### Target number of participants

740

#### Total final enrolment

733

#### Key exclusion criteria

Exclusion criteria at R1:

1. Smouldering MM, MGUS, solitary plasmacytoma of bone, or extramedullary plasmacytoma (without evidence of MM)

2. Received previous treatment for MM, with the exception of local radiotherapy to relieve bone pain or spinal cord compression, prior bisphosphonate treatment, or corticosteroids as long as the total dose does not exceed the equivalent of 160 mg dexamethasone

3. Known resistance, intolerance or sensitivity to any component of the planned therapies

4. Prior or concurrent invasive malignancies except the following:

4.1. Adequately treated basal cell or squamous cell skin cancer



- 4.2. Incidental finding of low grade (Gleason 3+3 or less) prostate cancer requiring no intervention
- 4.3. Adequately treated carcinoma in situ of the breast or cervix no longer requiring medical or surgical intervention
- 4.4. Any cancer from which the subject has been disease-free for at least 3 years
5. Pregnant, lactating or breastfeeding female participants
6. Major surgery within 14 days before randomisation. This would include surgical intervention for relief of cord compression but does not include vertebroplasty or kyphoplasty
7. Systemic treatment, within 14 days before the first dose of ixazomib with strong CYP3A inducers (e.g. rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St John's wort
8. Any concomitant drug therapy which, in the opinion of the investigator, may lead to an unacceptable interaction with any of the agents ixazomib, lenalidomide, dexamethasone, and that cannot be safely stopped prior to trial entry. Full details of interactions can be found in the SPCs
9. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of trial treatment, including difficulty swallowing
10.  $\geq$  Grade 2 peripheral neuropathy
11. Known HIV positive
12. Participant has current or prior hepatitis B surface antigen-positive or hepatitis C antibody positive. Participants must have screening conducted within 14 days before R1
13. Active systemic infection
14. Any other medical or psychiatric condition which, in the opinion of the investigator, contraindicates the participant's participation in this study
15. Receipt of live vaccination within 30 days prior to R1

#### Exclusion criteria for R2:

1. Received any anti-myeloma therapy other than their randomised trial treatment, with the exception of local radiotherapy to relieve bone pain (in the absence of disease progression), or bisphosphonate treatment
2. SD or disease progression according to the IMWG Uniform Response Criteria for Multiple Myeloma (see Appendix 2)
3. Known resistance, intolerance or sensitivity to ixazomib or lenalidomide that required cessation of either agent during induction
4. Developed any malignancy since R1 except the following:
  - 4.1. Adequately treated basal cell or squamous cell skin cancer
  - 4.2. Incidental finding of low grade (Gleason 3+3 or less) prostate cancer requiring no intervention
  - 4.3. Adequately treated carcinoma in situ of the breast or cervix no longer requiring medical or surgical intervention
5. Pregnant, lactating or breastfeeding female participants
6. Major surgery within 14 days before randomisation. This does not include vertebroplasty or kyphoplasty
7. Systemic treatment, within 14 days before the first dose of ixazomib with strong CYP3A inducers (e.g. rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St John's wort
8. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of trial treatment, including difficulty swallowing
9.  $\geq$  Grade 2 peripheral neuropathy, or grade 1 with pain
10. Known HIV positive
11. Current or known hepatitis B surface antigen positive or hepatitis C antibody positive
12. Active systemic infection

13. Any other medical or psychiatric condition which, in the opinion of the investigator, contraindicates the participant's continued participation in this study

14. Receipt of live vaccination within 30 days prior to R1 or receipt of live vaccination at any point during the trial prior to R2

**Date of first enrolment**

04/08/2020

**Date of final enrolment**

04/02/2024

## **Locations**

**Countries of recruitment**

England

Scotland

United Kingdom

Wales

**Study participating centre**

**Royal Devon & Exeter Hospital**

Barrack Road Devon

Exeter

United Kingdom

EX2 5DW

**Study participating centre**

**Cheltenham Hospital**

Sandford Road

Cheltenham

United Kingdom

GL53 7AN

**Study participating centre**

**James Cook University Hospital**

Marton Road

Middlesbrough

United Kingdom

TS4 3BW

**Study participating centre**  
**Singleton Hospital**  
Sketty Lane  
Swansea  
United Kingdom  
SA2 8QA

**Study participating centre**  
**Queen's Hospital Romford**  
Haematology & Oncology Department Queens Hospital  
Rom Valley Way  
Romford  
United Kingdom  
RM7 0AG

**Study participating centre**  
**Huddersfield Royal Infirmary**  
Acre Street  
Lindley  
Huddersfield  
United Kingdom  
HD3 3EA

**Study participating centre**  
**Calderdale Royal Hospital**  
Halifax  
United Kingdom  
HX3 0PW

**Study participating centre**  
**Sunderland Royal Hospital**  
Kayll Road  
Sunderland  
United Kingdom  
SR4 7TP

**Study participating centre**  
**South Tyneside Hospital**  
Harton Lane

South Shields  
United Kingdom  
NE34 0PL

**Study participating centre**  
**Kent and Canterbury Hospital**  
Ethelbert Road  
Canterbury  
United Kingdom  
CT1 3NG

**Study participating centre**  
**William Harvey Hospital**  
Kennington Road  
Willesborough  
Ashford  
United Kingdom  
TN24 0LZ

**Study participating centre**  
**Queen Elizabeth Hospital the Queen Mother**  
St Peters Road  
Margate  
United Kingdom  
CT9 4AN

**Study participating centre**  
**Colchester Hospital**  
Turner Road  
Colchester  
United Kingdom  
CO4 5JL

**Study participating centre**  
**Gloucestershire Royal Hospital**  
Great Western Road  
Gloucester  
United Kingdom  
GL1 3NN

**Study participating centre**  
**Kettering General Hospital**  
Rothwell Road  
Kettering  
United Kingdom  
NN16 8UZ

**Study participating centre**  
**Kings College Hospital**  
Denmark Hill  
London  
United Kingdom  
SE5 9RS

**Study participating centre**  
**Princess Royal University Hospital**  
Farnborough Common  
Orpington  
United Kingdom  
BR6 8ND

**Study participating centre**  
**Blackpool Victoria Hospital**  
Whinney Heys Road  
Blackpool  
United Kingdom  
FY3 8NR

**Study participating centre**  
**Trafford General Hospital**  
Moorside Road  
Davyhulme  
Manchester  
United Kingdom  
M41 5SL

**Study participating centre**  
**Manchester Royal Infirmary**  
Oxford Road  
Manchester

United Kingdom  
M13 9WL

**Study participating centre**  
**Wythenshaw Hospital**  
Southmoor Road  
Wythensahwe  
Manchester  
United Kingdom  
M23 9LT

**Study participating centre**  
**Freeman Hospital**  
High Heaton Tyne and Wear  
Newcastle Upon Tyne  
United Kingdom  
NE7 7DN

**Study participating centre**  
**Aberdeen Royal Infirmary**  
Foresterhill Road  
Aberdeen  
United Kingdom  
AB25 2ZN

**Study participating centre**  
**Ninewells Hospital**  
Dundee  
United Kingdom  
DD1 9SY

**Study participating centre**  
**Norfolk & Norwich University Hospital**  
Colney Lane  
Norwich  
United Kingdom  
NR4 7UY

**Study participating centre**

**Southmead Hospital**

Bristol  
United Kingdom  
BS10 5NB

**Study participating centre**

**Peterborough City Hospital**

Edith Cavell Campus  
Bretton Gate  
Peterborough  
United Kingdom  
PE3 9GZ

**Study participating centre**

**Hinchingbrooke Hospital**

Huntingdon  
United Kingdom  
PE29 6NT

**Study participating centre**

**Nottingham City Hospital**

Hucknall Road  
Nottingham  
United Kingdom  
NG5 1PB

**Study participating centre**

**Royal Berkshire Hospital**

London Road  
Reading  
United Kingdom  
RG1 5AN

**Study participating centre**

**Royal Bournemouth Hospital**

Castle Lane East  
Bournemouth  
United Kingdom  
BH7 7DW

**Study participating centre**  
**Friarage Hospital**  
Northallerton  
United Kingdom  
DL6 1JG

**Study participating centre**  
**St George's Hospital**  
Blackshaw Road  
London  
United Kingdom  
SW17 0QT

**Study participating centre**  
**St Helens Hospital**  
Marshalls Cross Road  
St. Helens  
United Kingdom  
WA9 3DA

**Study participating centre**  
**Whiston Hospital**  
Warrington Road  
Prescot  
United Kingdom  
L35 5DR

**Study participating centre**  
**Torbay Hospital**  
Lowes Bridge  
Torquay  
United Kingdom  
TQ2 7AA

**Study participating centre**  
**Bristol Haematology & Oncology Centre**  
Bristol Royal Infirmary  
King Edward Yard  
Marlborough Hill  
Bristol



United Kingdom  
BS2 8HW

**Study participating centre**

**Royal Derby Hospital**

Uttoxeter Road  
Derby  
United Kingdom  
DE22 3NE

**Study participating centre**

**University College London Hospital**

235 Euston Road  
London  
United Kingdom  
NW1 2BU

**Study participating centre**

**Royal Albert Edward Infirmary**

Wigan Lane  
Wigan  
United Kingdom  
WN1 2NN

**Study participating centre**

**Leicester Royal Infirmary**

Aylestone Road  
Leicester  
United Kingdom  
LE2 7LG

**Study participating centre**

**Derriford Hospital**

Derriford Road  
Crownhill  
Plymouth  
United Kingdom  
PL6 8DH

**Study participating centre****Worthing Hospital**

Lyndhurst Road  
Worthing  
United Kingdom  
BN11 2DH

**Study participating centre****St Richards Hospital**

Spitafield Lane  
Chichester  
United Kingdom  
PO19 6SE

**Study participating centre****The County Hospital**

Stonebow  
Road Hereford  
United Kingdom  
HR1 2BN

## **Sponsor information**

**Organisation**

University of Leeds

**Sponsor details**

UoL/LTHT Joint Sponsor QA Office (CTIMPs)  
St James' University Hospital  
Leeds  
England  
United Kingdom  
LS2 9JT  
+44 (0)1133432813  
ctru\_myelomaxiv@leeds.ac.uk

**Sponsor type**

University/education

**Website**

<http://www.leeds.ac.uk>

# Funder(s)

## Funder type

Charity

## Funder Name

Cancer Research UK

## Alternative Name(s)

CR\_UK, Cancer Research UK - London, CRUK

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

United Kingdom

## Funder Name

Takeda Pharmaceuticals International

## Alternative Name(s)

Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals International GmbH

## Funding Body Type

Private sector organisation

## Funding Body Subtype

For-profit companies (industry)

## Location

Switzerland

## Funder Name

Celgene

## Alternative Name(s)

Celgene Corporation

## Funding Body Type

Private sector organisation

**Funding Body Subtype**

For-profit companies (industry)

**Location**

United States of America

## Results and Publications

**Publication and dissemination plan**

Current publication and dissemination plan as of 04/07/2022:

Data from this study will be published once trial endpoints have been reached and after the overall trial end date. Publication will be via peer-reviewed journals as well as via presentations at conferences. The results will also be available on UK cancer websites such as Myeloma UK and Cancer Research UK.

Previous publication and dissemination plan:

The protocol is not currently available. A protocol publication, based on the RADAR protocol will be available at a later date. Data from this study will be published once trial endpoints have been reached and after the overall trial end date. Publication will be via peer-reviewed journals as well as via presentations at conferences. The results will also be available on UK cancer websites such as Myeloma UK and Cancer Research UK.

**Intention to publish date**

31/08/2028

**Individual participant data (IPD) sharing plan**

De-identified individual participant data datasets generated and/or analysed during the current study will be available upon request from the Clinical Trials Research Unit, University of Leeds (contact CTRU-DataAccess@leeds.ac.uk in the first instance). Data will be made available at the end of the trial, i.e. usually when all primary and secondary endpoints have been met and all key analyses are complete. Data will remain available from then on for as long as CTRU retains the data.

CTRU makes data available by a 'controlled access' approach. Data will only be released for legitimate secondary research purposes, where the Chief Investigator, Sponsor and CTRU agree that the proposed use has scientific value and will be carried out to a high standard (in terms of scientific rigour and information governance and security), and that there are resources available to satisfy the request. Data will only be released in line with participants' consent, all applicable laws relating to data protection and confidentiality, and any contractual obligations to which the CTRU is subject. No individual participant data will be released before an appropriate agreement is in place setting out the conditions of release. The agreement will govern data retention, usually stipulating that data recipients must delete their copy of the released data at the end of the planned project.

The CTRU encourages a collaborative approach to data sharing and believes it is best practice for researchers who generated datasets to be involved in subsequent uses of those datasets. Recipients of trial data for secondary research will also receive data dictionaries, copies of key trial documents and any other information required to understand and reuse the released datasets.

The conditions of release for aggregate data may differ from those applying to individual participant data. Requests for aggregate data should also be sent to the above email address to discuss and agree on suitable requirements for release.

## IPD sharing plan summary

Available on request

## Study outputs

| Output type                          | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|--------------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Protocol article</a>     |         | 02/06/2022   | 08/06/2022 | Yes            | No              |
| <a href="#">HRA research summary</a> |         |              | 28/06/2023 | No             | No              |